In this issue:
Avelumab + axitinib vs sunitinib for advanced RCC
Pembrolizumab + axitinib vs sunitinib for advanced RCC
HRQoL of patients with advanced RCC treated with nivolumab + ipilimumab vs sunitinib
Cost-effectiveness of first-line nivolumab + ipilimumab vs sunitinib for metastatic RCC
Germline mutations in cancer susceptibility genes in advanced RCC
Comparative effectiveness of management options for patients with small renal masses
Cabozantinib in advanced non-clearcell RCC
Immediate vs deferred cytoreductive nephrectomy in patients with synchronous metastatic RCC receiving sunitinib
Abnormal oxidative metabolism in CCPAP tumours
Efficacy and safety of an individualised schedule of sunitinib for metastatic RCC
Please login below to download this issue (PDF)